IP Library Granted Patent US 11,931,463
Granted Patent B2
US 11,931,463 · App. 17/408,111 · Granted Mar 19, 2024

All-in-one fixed-dose combination for treating

Inventors: Reza Fathi (Oradell, NJ); Gilead Raday (Palo Alto, CA); Guy Goldberg (Tel Aviv, IL); Patrick Gosselin (Laval, CA)
Assignee: RedHill Biopharma Ltd.
A61K9/4808A61K9/4866A61K9/4891A61K9/5026A61K9/5047A61K9/5084A61K31/395A61K31/43A61K31/435A61K31/438A61K31/4439
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,931,463
App. No.
17/408,111
Granted
Mar 19, 2024
Kind
B2
Abstract

Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.

Claims (23)

1. An all-in-one capsule comprising:

about 12.5 mg rifabutin;

about 250 mg amoxicillin; and

about 10 mg omeprazole,

wherein the omeprazole is in the form of a first plurality of minitablets.

2. The solid oral dosage form of claim 1 wherein the omeprazole is an equivalent amount of omeprazole magnesium.

3. The solid oral dosage form of claim 1 wherein the capsule includes a second plurality of minitablets, wherein each minitablet of the second plurality of minitablets comprises a mixture of amoxicillin and rifabutin.

4. The solid oral dosage form of claim 3 wherein the minitablets of the second plurality of minitablets have a size in the range of from about 100 μm to 2 mm.

5. The solid oral dosage form of claim 1 wherein the omeprazole minitablets are coated with a protective coat.

6. The solid oral dosage form of claim 5 wherein the protective coat is an enteric coating.

7. The solid oral dosage form of claim 1 wherein the minitablets of the first plurality of minitablets have a size in the range of from about 100 μm to 2 mm.

8. A packaged pharmaceutical preparation comprising a plurality of the capsules of claim 1 in a sealed container and instructions for administering them to treat a patient infected with H. pylori.

9. The packaged pharmaceutical preparation of claim 8 comprising a 14 day supply of the capsules.

10. A method for treating H. pylori infection comprising orally administering each day, for an effective period of time, a plurality of the all-in-one capsules of claim 1 to a human having an H. pylori infection.

11. The method of claim 10 comprising orally administering each day, for an effective period of time, twelve all-in-one capsules.

12. The method of claim 11 comprising orally administering each day, for an effective period of time, twelve all-in-one capsules, wherein the administering occurs at three different time points throughout the day.

13. The method of claim 10 wherein the effective period of time is 14 days.

14. An all-in-one capsule comprising:

about 12.5 mg rifabutin;

about 250 mg amoxicillin trihydrate; and

about 10 mg omeprazole,

wherein the omeprazole is in the form of a first plurality of minitablets.

15. The all-in-one capsule of claim 14 , wherein the rifabutin and the amoxicillin trihydrate within the capsule are in the form of a second plurality of minitablets, wherein each minitablet of the second plurality of minitablets comprises a mixture of the rifabutin and the amoxicillin trihydrate.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2023
From: FATHI, REZA; RADAY, GILEAD; GOLDBERG, GUY; GOSSELIN, PATRICK
To: REDHILL BIOPHARMA LTD.
Reel/Frame 062425/0540 →